Spyre Therapeutics(US:SYRE) The Motley Fool·2026-01-11 14:17Company Overview - Spyre Therapeutics is a preclinical biotechnology company specializing in innovative antibody-based therapies for inflammatory bowel disease (IBD) [7] - The company focuses on novel mechanisms and combination biologics to address significant unmet needs in gastrointestinal medicine [7] - Spyre Therapeutics has a robust pipeline and expertise in monoclonal antibody development, aiming to establish a competitive edge in the IBD therapeutic landscape [7] Financial Metrics - The company's market capitalization is $2.3 billion [6] - Spyre Therapeutics has 73 employees [6] - The net income for the trailing twelve months (TTM) is -$127.7 million [6] - The stock price as of market close on January 2 was $30.58 [6] Recent Insider Activity - CEO Cameron Turtle sold 15,000 shares on January 2 for a total consideration of approximately $460,134 [2][3] - After the sale, Turtle retained about 671,907 shares valued at approximately $20.5 million [5] - The 15,000-share sale accounted for 2.2% of Turtle's direct ownership [8] Stock Performance - Over the past year through January 9, Spyre Therapeutics' shares gained 36.3%, outperforming the Nasdaq Composite's total return of 24.3% [11]